Compositions and use of m-csf-alpha

The invention is a method and composition for reducing a population of diseased cells by administration of a gene delivery vehicle capable of expressing an M-CSF alpha mutant having a decreased capacity to be proteolytically processed and released from a cell membrane. The invention is also a combin...

Full description

Saved in:
Bibliographic Details
Main Authors VAVARANI DWARKI, KIRSTON E. KOTHS, WILLIAM C. MANNING
Format Patent
LanguageEnglish
Published 22.09.1998
Edition6
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The invention is a method and composition for reducing a population of diseased cells by administration of a gene delivery vehicle capable of expressing an M-CSF alpha mutant having a decreased capacity to be proteolytically processed and released from a cell membrane. The invention is also a combination of therapeutic agents including gene delivery vehicles expressing M-CSF alpha or an M-CSF alpha mutant in combination, for example, either with a soluble M-CSF, an M-CSF alpha convertase inhibitor, or a gene delivery vehicle expressing prodrug activator such as thymidine kinase followed by administration of the prodrug.
Bibliography:Application Number: AU19980064588